Bial-Portela, Neurocrine Biosciences deal

Bial-Portela granted Neurocrine Biosciences exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370). Bial-Portela will

Read the full 173 word article

User Sign In